D
David J. Hosking
Researcher at University of Nottingham
Publications - 134
Citations - 10711
David J. Hosking is an academic researcher from University of Nottingham. The author has contributed to research in topics: Osteoporosis & Bone remodeling. The author has an hindex of 48, co-authored 134 publications receiving 10354 citations. Previous affiliations of David J. Hosking include University of Texas Health Science Center at San Antonio & Nottingham City Hospital.
Papers
More filters
Journal ArticleDOI
Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy
John M Monaghan,Ian M Godber,Nigel Lawson,Malveen Kaur,Gwen Wark,Derrick Teale,David J. Hosking +6 more
TL;DR: The data on the physiological changes of IGFs and their binding proteins add further evidence of the vital roles of these hormones throughout normal pregnancy.
Journal ArticleDOI
The management of primary hyperparathyroidism.
TL;DR: The recommendations are based on an electronic search spanning the past decade using the search terms hyperparathyroidism, management and parathyroidectomy/surgery, but the findings have also included key publications outside this period.
Journal ArticleDOI
A comparison of calcaneal dual-energy X-ray absorptiometry and calcaneal ultrasound for predicting the diagnosis of osteoporosis from hip and spine bone densitometry.
TL;DR: The optimal T-score for pDXA from ROC analysis was -1.7 and for QUS was -2.4, similar to the manufacturer's recommendations.
Journal ArticleDOI
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : Results of FACTS1-international
David M. Reid,David J. Hosking,David L. Kendler,Maria Luisa Brandi,John D. Wark,Georges Weryha,João Francisco Marques-Neto,Keavy A. Gaines,N. Verbruggen,Mary E. Melton +9 more
TL;DR: Alendronic acid once weekly produced greater BMD increases at both hip and spine sites and greater reductions in bone turnover relative to risedronic acidonce weekly, and both agents were well tolerated with no significant difference in upper gastrointestinal adverse experiences.
Journal ArticleDOI
Medical management of hypercalcemia.
Stuart H. Ralston,Robert E. Coleman,William D. Fraser,S. J. Gallagher,David J. Hosking,J. S. Iqbal,Eugene V. McCloskey,D. Sampson +7 more
TL;DR: Medical Management of Hypercalcemia S. H. Ralston, R. J. Hosking, J. S. Iqbal, E. McCloskey, D. Gallagher, S. Fraser, and S10 2SJ.